Antibiotic Resistance

Antibiotic Resistance – Global

Antibiotic resistance is one of the main threats to global health, food security, and development today. While antibiotic resistance is a naturally occurring phenomenon, it has been dangerously accelerated due to the misuse of antibiotics in humans and animals. As the number of antibiotic-resistant bacteria is growing, it is threatening our ability to treat common infectious diseases such as pneumonia or urinary tract infections and hindering our ability to keep using antibiotics to aid other life-saving treatments, such as chemotherapy and radiotherapy.

Antibiotic resistance has first been noted by Alexander Fleming, alongside his ground-breaking discovery of the first antibiotic, penicillin.  When accepting his Nobel Peace Prize for penicillin, at the time hailed as the “miracle drug’’, he warned of the dangers of unchecked and chaotic use of antibiotics, stating that this will eventually render the drugs useless and once again leave us defenceless in front of infections.

Without urgent national and international action, we are heading towards a post-antibiotic era, in which common infections and minor injuries can kill once again. The WHO has estimated that by 2050, antibiotic resistance will become the biggest killer in the world, killing an estimated 10 million per year, more than even cancer. Antibiotic resistance is already currently taking an estimated 700,000 lives each year.

The rise of antibiotic resistance is not only a national problem but a global problem as well, mainly due to the nature of antibiotic-resistant bacteria. Bacteria are constantly evolving and changing, they can not only adapt resistant mechanisms on their own, but they can even transfer their genetic material encompassing resistant mechanisms onto other bacteria or in the environment around it.  The transfer of bacteria can occur from human to human, human to animal, or vice versa or through the environment. Due to its versatility, bacteria are often impossible to contain and measures usually used in viral outbreaks, such as the recent COVID-19 lockdowns, would not be able to effectively target it.

Bacteria resistance to a huge number of antibiotics has already occurred, with the most notable ones being carbapenem-resistant Enterobacteriaceae, MRSA, Vancomycin-resistant Enterococci, and Mycobacterium tuberculosis. The Carbapenem-resistant Enterobacteriaceae are resistant to the carbapenem class of antibiotics, considered the last resort antibiotic in Enterobacteriaceae infections. This means that bacteria such as Escherichia coli and Klebsiella pneumonia are no longer treatable, leaving patients to die from previously treatable diseases such as pneumonia. In the same way, Mycobacterium tuberculosis can lead to tuberculosis becoming incurable. Long-term exposure to MRSA, the Methicillin-resistant Staphylococcus aureus, can lead to skin infections, urinary tract infections, and even sepsis. This specific bacteria is often found in hospitals, with MRSA bacteria gained from hospitals being more likely to lead to complications.

The brunt of antibiotic resistance will be disproportionately focused on low and middle-income countries, mainly due to the poor health care systems present. Due to the highly spreadable nature of bacteria, poor health care systems won’t be able to keep up and prevent or contain antibiotic-resistant bacteria. In these countries, antibiotics are often handed out without prescriptions and their use is not monitored in hospitals or pharmacies. This not only increases the prevalence of antibiotic-resistant bacteria but also creates more chances for the bacteria to communicate and evolve resistant mechanisms. Additionally, the high use of antibiotics in animal agriculture in these countries has already lead to the creation and spread of several antibiotic-resistant bacteria. A prime example would be the appearance of colistin-resistant bacteria in 2016 on a farm in China, where colistin was often used in animal agriculture. Colistin is considered the last resort antibiotic for all infections and is very seldom prescribed in practice unless absolutely necessary due to the side effects associated with the strong drug. China has since banned the use of colistin in animal agriculture. However, colistin-resistant bacteria has already spread to all continents and some low-income countries still use it for livestock.

There have been various responses to this crisis, the WHO and EU have each developed an AMR action plan, with all EU nations developing their own national AMR action plan as well. Both the WHO and the EU have stated that the EU will act as a role model for combating antibiotic resistance. However, the implementation of these plans has encountered several difficulties. From lack of funding, lack of skilled personnel, and lack of proper information centres, these difficulties make it impossible for countries to effectively tackle AMR. With the lack of funding available for the creation of antibiotics, there are very few in the making today. It takes around 1 billion dollars to create antibiotics and around 10 years of research. However, pharmaceutical companies have decided to no longer create antibiotics, as they would not bring back profit. Due to the constantly evolving nature of antibiotic-resistant bacteria, a new antibiotic would only be good for a few years under the current circumstances in the healthcare and animal agriculture sectors, before a bacteria resistant to it is discovered.

"The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism."

Key Facts


People killed per year (aprox.)


Estimated deaths by 2050

Ongoing since



Major Outbreaks


  • Carbapenem-resistant Acinetobacter

These bacteria are now multi-drug resistant and if untreated they can cause blood, lungs, urinary tract infections, and open wounds.

They are often found in the environment, in soil or in water and tend to spread fast in intensive care units.

The WHO declared this outbreak as an immediate emergency, mainly due to the significantly high death rate of approx. 50%.

Where: Global (areas of concern: USA, Europe, Asia, Australia, Israel & South Africa)

  • Methicillin-resistant Staphylococcus aureus (MRSA)

These bacteria are multi-drug resistant and are responsible for several severe infections that are now very difficult to treat. If untreated, MRSA usually manifests as a red bump on the skin accompanied by a fever, both symptoms getting worse over time and becoming life-threatening.

As MRSA originated from a hospital setting, it is very commonplace in hospitals, nursing homes, and other healthcare settings. While it affects everyone, it is particularly devastating to those with weak immune systems or those who have recently undergone surgery.

Where: Global

  • Candida Auris

This fungus is resistant to multiple antifungal medications and if untreated can lead to severe candida infections which in time turn life-threatening.

Another area of concern regarding this outbreak is the difficulty with which it can be identified, making it very easy to miss in hospital settings. Many outbreaks have occurred in intensive care units due to this. The WHO has stated that it might even be responsible for around 600,000 infections each year worldwide.

Where: Global (areas of concern: USA, Spain, India, Venezuela, Pakistan)

  • Clostridioides difficile

These bacteria are multi-drug resistant and most commonly affect people who have recently been treated with antibiotics. If untreated this can lead to severe diarrhea and colitis and can be life-threatening in the long run.

Where: Global

  • Carbapenem-resistant Enterobacterales

These bacteria are often referred to as nightmare bacteria, due to their high mortality rate, their vast resistant mechanisms, and high spreadability. They are often immune to most existing antibiotics with some of them proving to even be immune to all existing antibiotics. If untreated, they can leave people with untreatable infections which will eventually lead to death.

Depending on the strain, Enterobacterales can have various effects, from pneumonia due to the Klebsiella pneumoniae bacteria to severe diarrhea and colon damage from Escherichia coli.

Where: Global

  • Drug-resistant Neisseria gonorrhoeae

These bacteria are multi-drug resistant and a large portion of them have now even developed resistance to the standard combination antibiotic therapy opted for by most healthcare systems worldwide. If untreated, these bacteria can cause gonorrhea, a sexually transmitted disease that causes pain during urination, discharge and can lead to life-threatening complications such as pelvic inflammatory disease or septic arthritis.

Where: Global (areas of concern: Denmark, France, Japan & United Kingdom)

  • Drug-resistant Campylobacter

These bacteria are now multi-drug resistant and infections with resistant strains usually take longer to treat and lead to a higher risk of severe complications. If untreated, these bacteria can lead to severe diarrhea which in time can lead to life-threatening complications.

These bacteria are usually transmitted through contaminated water or food and can be found in undercooked or raw meat.

The CDC has declared that in 2017, around 25% of all Campylobacter bacteria was now resistant to its first-line treatment, ciprofloxacin.

Where: Global

  • ESBL-producing Enterobacteriaceae

These bacteria have learned to produce a specific enzyme called ESBL which works in breaking down antibiotics, rendering them ineffective. Depending on the strain, Enterobacterales can have various effects, from pneumonia due to the Klebsiella pneumoniae bacteria to severe diarrhea and colon damage from Escherichia coli.

Where: Global (areas of concern: Germany, Africa, USA)

  • Vancomycin-resistant Enterococci (VRE)

These bacteria have developed resistance to their first-line treatment, vancomycin, and they are commonly spread through poor hygiene. If untreated, these bacteria can cause an array of symptoms, from blood and urinary tract infections to infections of surgical or open wounds. The CDC has reported approx. 5,000 deaths in 2019 due to this resistant strain.

Where: Global

  • Multidrug-resistant Pseudomonas aeruginosa

These bacteria are now multi-drug resistant and if untreated can lead to blood and lung infections, as well as infections in areas of the body that have recently undergone surgery. It specifically targets people within intensive care units that are on breathing machines, use catheters, have suffered burns, or have recently undergone surgery.

Where: Global

  • Drug-resistant nontyphoidal Salmonella

These bacteria are multi-drug resistant and If untreated can lead to severe diarrhea, high fevers, and focal infections. The most common sources of these bacteria are raw and undercooked meat, eggs, and raw milk or direct contact with infected animals. The overexposure of these animals to antibiotics might be the main contributor to the rise of drug-resistant Salmonella.

Where: Global

  • Drug-resistant Streptococcus pneumoniae

These bacteria are multi-drug resistant and if untreated, can lead to bacterial pneumonia and meningitis. There is currently a vaccine for these bacteria that help prevent infections called the PCV vaccine.

Where: Global

  • Drug-resistant Tuberculosis

These bacteria are now multi-drug resistant and are responsible for Tuberculosis. This disease manifests through a thick cough, sometimes presenting blood as well, fatigue, fever, and chest pain. While it mainly targets the lungs, it can also spread to other parts of the body including the glands, bones, nervous system, and abdomen.

While TB used to be completely curable, those infected with drug-resistant strains can no longer be treated and face more severe infections.

Where: Global

The Key Actors

The Situation


  • Endemic

Analyst’s suggestions:

A stronger focus on AMR evidence based-policy making, as there numerous sources of information on AMR spread and very few policies addressing these.

Policies to address and hinder the standardisation of national actions plans to mimic the WHO and EU action plans without addressing each country’s specific AMR needs.

A call for a global coordinated AMR monitoring system.

Action taken by governments and pharmaceutical companies to develop more antibiotics instead of relying on the hopes that an alternative to antibiotics might be discovered.

The creation of a shared pool of AMR data, data collection and technical tools similar to the original C-TAP Covid-19 access pool and the strong stance against IP centred knowledge pools. 

More effective funding systems for AMR research and policy making.

AMR awareness programmes and training events for hospital staff on proper AMR containment and monitoring.



In November 2021, The Food and Agricultural Organization has declared we may soon be reaching the tipping point for AMR related deaths to start exponentially rising and becoming the number 1 cause of death worldwide. FAO-OIE-UNEP-WHO joint platform was declared in November 2021 during Antimicrobial Awareness Week in order to deal with AMR in Europe and Central Asia. Dr Hans Henri P. Kluge, WHO Regional Director for Europe stated that AMR is being pushed towards the back of the agenda, with Covid-19 staying at the fore front of health crises. However, he warns against the persistent lack of urgency relating to AMR. With the WHO declaring Antimicrobial resistance as one of the top 10 global threats to public health, AMR continues to rise. Resistance rates have even reached an approx 92% for some antibiotics. Antimicrobial resistance is currently responsible for approx. 700,000 deaths worldwide each year and the death rate is expected to rise to a concerning 10,000,000 within the next few decades.

The WHO, EU and national AMR combat plans worldwide have succeeded in lowering AMR infection rates in certain cases, however, they are not enough to keep the public health crisis from growing. These plans have generally failed to tackle hospital transmissions, animal agriculture AMR policies and do not raise enough awareness of the issue throughout the public.

The WHO in partnership with the Drugs for Neglected Diseases Initiative have committed to developing 5 new treatments for the most dangerous resistant bacteria by 2025. However, with the current COVID-19 pandemic taking all the focus from other public health concerns, it seems this might end up being delayed.

As of December 2019, only 42 new antibiotics have gone into clinical development, with only 4 of them hitting the market by today. The most popular AMR combat mechanisms in development, phage therapy, is currently facing a patent and intellectual property crisis Phage therapy scientists have warned that without the opening up of patents and the relaxation of intellectual property rights in the pharmaceutical industry, the further development of the antibiotic replacement therapy will eventually come to a halt and won’t be able to keep up with the AMR crisis.

Timeline of Events

More on this Crisis

Opportunities in the Crisis Index

If you have relevant knowledge of a particular region and are interested in being a Regional Crisis Adviser or Senior Correspondent (Crisis Index), please email our Crisis Index Coordinator at

Interested incontributing to the Crisis Index?

We have a team of knowledgeable advisors and senior correspondents responsible for updating and maintaining our Crisis Index pages. For more information on the roles and responsibilities, click the button below.
Click Here